Herm Rosenman
CIK: 0001230057
Associated companies
Transaction History
| NTRA | ▲ Buy | Grant | 106 | — | 6/26/2026 | View on chart |
| NTRA | ▲ Buy | Grant | 1,571 | — | 6/26/2026 | View on chart |
| NTRA | ▼ Sell | Open Market | 16,530 | $4.1M | 6/24/2026 | View on chart |
| NTRA | ▲ Buy | Grant | 222 | — | 4/24/2026 | View on chart |
| NTRA | ▲ Buy | Grant | 117 | — | 4/24/2026 | View on chart |
| NTRA | ▲ Buy | Grant | 99 | — | 1/30/2026 | View on chart |
| NTRA | ▼ Sell | Open Market | 14,372 | $3.3M | 12/12/2025 | View on chart |
| NTRA | ▼ Sell | Open Market | 21,910 | $5.0M | 12/12/2025 | View on chart |
| NTRA | ▼ Sell | Open Market | 11,987 | $2.7M | 12/12/2025 | View on chart |
| NTRA | ▼ Sell | Open Market | 150 | $34K | 12/12/2025 | View on chart |
| NTRA | ▲ Buy | Grant | 132 | — | 10/31/2025 | View on chart |
| NTRA | ▲ Buy | Grant | 153 | — | 7/25/2025 | View on chart |
| NTRA | ▲ Buy | Grant | 271 | — | 6/27/2025 | View on chart |
| NTRA | ▲ Buy | Grant | 2,143 | — | 6/27/2025 | View on chart |
| NTRA | ▲ Buy | Grant | 164 | — | 4/25/2025 | View on chart |
| NTRA | ▲ Buy | Grant | 133 | — | 1/31/2025 | View on chart |
| NTRA | ▲ Buy | Grant | 178 | — | 10/25/2024 | View on chart |
| NTRA | ▲ Buy | Grant | 206 | — | 7/26/2024 | View on chart |
| NTRA | ▲ Buy | Grant | 2,964 | — | 6/28/2024 | View on chart |
| NTRA | ▲ Buy | Grant | 488 | — | 4/26/2024 | View on chart |
| NTRA | ▲ Buy | Grant | 244 | — | 4/26/2024 | View on chart |
| NTRA | ▼ Sell | Open Market | 35,947 | $2.5M | 2/16/2024 | View on chart |
| NTRA | ▲ Buy | Option Exercise | 93,901 | $249K | 2/16/2024 | View on chart |
| NTRA | ▼ Sell | Open Market | 57,954 | $4.0M | 2/16/2024 | View on chart |
| NTRA | ▲ Buy | Grant | 303 | $19K | 1/26/2024 | View on chart |
| NTRA | ▲ Buy | Grant | 454 | $19K | 10/27/2023 | View on chart |
| NTRA | ▲ Buy | Grant | 380 | $18K | 7/28/2023 | View on chart |
| NTRA | ▲ Buy | Grant | 2,750 | — | 6/30/2023 | View on chart |
| NTRA | ▲ Buy | Option Exercise | 3,534 | — | 5/25/2023 | View on chart |
| NTRA | ▲ Buy | Grant | 331 | $18K | 4/14/2023 | View on chart |
| NTRA | ▲ Buy | Grant | 453 | $18K | 1/13/2023 | View on chart |
| NTRA | ▲ Buy | Grant | 399 | $18K | 10/14/2022 | View on chart |
| NTRA | ▲ Buy | Option Exercise | 1,307 | — | 5/25/2022 | View on chart |
| NTRA | ▲ Buy | Option Exercise | 44,503 | $118K | 11/8/2021 | View on chart |
| NTRA | ▼ Sell | Open Market | 39,171 | $671K | 11/8/2021 | View on chart |
| NTRA | ▼ Sell | Open Market | 2,100 | $249K | 11/8/2021 | View on chart |
| NTRA | ▼ Sell | Open Market | 2,832 | $339K | 11/8/2021 | View on chart |
| NTRA | ▼ Sell | Open Market | 400 | $48K | 11/8/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Natera Named to TIME Best Inventions, Gets PT Hikes
Natera's Signatera test was named to TIME's Best Inventions of 2026, highlighting its clinical relevance. The company also announced a collaboration with TransCode Therapeutics for a colorectal cancer trial. Morgan Stanley and TD Cowen recently raised their price targets, reflecting strong analyst confidence in the stock's trajectory.
Natera Named to TIME Best Inventions, Gets PT Hikes. Natera's Signatera test was named to TIME's Best Inventions of 2026, highlighting its clinical relevance. The company also announced a collaboration with TransCode Therapeutics for a colorectal cancer trial. Morgan Stanley and TD Cowen recently raised their price targets, reflecting strong analyst confidence in the stock's trajectory.